FDA Greenlights Historical Control In Trial Of Regentis' GelrinC Knee Repair Material
Executive Summary
The pivotal clinical study will support a US pre-market approval to allow Regentis Biomaterials to market GelrinC for the repair of focal knee cartilage defects in the knee, the largest unmet need in orthopedic sports medicine, according to the company.